|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.32 USD | +2.79% |
|
+0.30% | -35.41% |
| 06-11 | Transcript : Vistagen Therapeutics, Inc., Q4 2024 Earnings Call, Jun 11, 2024 | |
| 06-11 | Vistagen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Vistagen Therapeutics, Inc. reported earnings results for the full year ended March 31, 2024. For the full year, the company reported revenue was USD 1.06 million compared to negative revenue of USD 0.227 million a year ago. Net loss was USD 29.36 million compared to USD 59.25 million a year ago.
Basic loss per share from continuing operations was USD 1.52 compared to USD 8.51 a year ago. Diluted loss per share from continuing operations was USD 1.52 compared to USD 8.51 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -35.41% | 87.29M | |
| +16.45% | 123B | |
| +21.96% | 115B | |
| +23.73% | 25.85B | |
| -20.05% | 20.9B | |
| -16.28% | 16.77B | |
| -16.52% | 16.52B | |
| -44.35% | 15.56B | |
| +63.91% | 15.49B | |
| +2.52% | 13.45B |
VISTAGEN THERAPEUTICS, INC. 
